Deciphera Pharmaceuticals (DCPH)

Deciphera Pharmaceuticals (DCPH) Stock Price & Analysis


DCPH Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$12.33 - $22.76
Previous Close$12.72
Average Volume (3M)399.69K
Market Cap
Enterprise Value$701.39M
Total Cash (Recent Filing)$328.74M
Total Debt (Recent Filing)$27.52M
Price to Earnings (P/E)-5.5
Nov 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding78,821,161
10 Day Avg. Volume361,764
30 Day Avg. Volume399,692
Standard Deviation0.20
Financial Highlights & Ratios
Price to Book (P/B)2.48
Price to Sales (P/S)26.65
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.91
Enterprise Value/Gross Profit5.60
Enterprise Value/Ebitda22.90
Price Target Upside49.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Deciphera Pharmaceuticals’s price range in the past 12 months?
Deciphera Pharmaceuticals lowest stock price was $12.33 and its highest was $22.76 in the past 12 months.
    What is Deciphera Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Deciphera Pharmaceuticals’s upcoming earnings report date?
    Deciphera Pharmaceuticals’s upcoming earnings report date is Nov 08, 2023 which is in 36 days.
      How were Deciphera Pharmaceuticals’s earnings last quarter?
      Deciphera Pharmaceuticals released its earnings results on Aug 09, 2023. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.62 by $0.05.
        Is Deciphera Pharmaceuticals overvalued?
        According to Wall Street analysts Deciphera Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Deciphera Pharmaceuticals pay dividends?
          Deciphera Pharmaceuticals does not currently pay dividends.
          What is Deciphera Pharmaceuticals’s EPS estimate?
          Deciphera Pharmaceuticals’s EPS estimate is -$0.61.
            How many shares outstanding does Deciphera Pharmaceuticals have?
            Deciphera Pharmaceuticals has 78,821,160 shares outstanding.
              What happened to Deciphera Pharmaceuticals’s price movement after its last earnings report?
              Deciphera Pharmaceuticals reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.62. Following the earnings report the stock price went up 6.182%.
                Which hedge fund is a major shareholder of Deciphera Pharmaceuticals?
                Among the largest hedge funds holding Deciphera Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Deciphera Pharmaceuticals’s shares valued at 94M.


                  Deciphera Pharmaceuticals Stock Smart Score

                  The Deciphera Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Deciphera Pharmaceuticals

                  Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.


                  Top 5 ETFs holding DCPH

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Schwab U.S. Broad Market ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold DCPH. The ETFs are listed according to market value of DCPH within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Aptose Biosciences
                  Bellicum Pharmaceuticals
                  Arrowhead Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis